36C24226N0216↗
Novartis Pharmaceuticals Corporation received this contract from 242-Network Contract Office 02 (36C242), Department of Veterans Affairs: $813.5K obligated so far for drugs and biologicals. It runs to 2026-10-31.
Key facts · data as of Oct 25, 2026
- Recipient
- Novartis Pharmaceuticals Corporation
- Awarding agency
- Department of Veterans Affairs
- Contracting office
- 242-Network Contract Office 02 (36C242) (36C242)
- Obligated to date
- $813.5K
- Potential value
- $813.5K
- Ends
- 2026-10-31
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 36C24226N0216, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_36C24226N0216_3600_36F79720D0180_3600
Novartis Pharmaceuticals Corporation: all federal awards · Department of Veterans Affairs: spending · 242-Network Contract Office 02 (36C242): what it buys · The follow-on: recompete brief
PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)
Up for re-bid: ends 2026-10-31. Recompete brief → · 6505--Notice of Intent to Sole-Source for Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) and Lutathera (Lutetium Lu 177 Dotatate) for Buffalo VA Medical Center ↗
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- 242-Network Contract Office 02 (36C242) (36C242)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 36F79720D0180
- Solicitation
- 36C24226Q0080
- Where the work is
- Morris, NJ · district NJ-11
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
2 actions since 2025-10-28. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-02-06 | P00001 | Supplemental agreement (work within scope) | $514.4K | PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML) |
| 2025-10-28 | 0 | $299.1K | PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML) |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗